Feb 11, 2021
AstraZeneca predicts pandemic will disrupt prescription sales
AstraZeneca cautioned of a tough year ahead as the pandemic disrupts prescription sales, with the drugmaker also planning for higher spending. For the fourth quarter AstraZeneca reported product sales of $7bn, up 12 per cent year on year, which beat the consensus forecast. The company said revenue increased by 13.5 per cent to £8.2bn for the nine months ending December, with fiscal third-quarter revenue growth of 20 per cent. RELX, the publishing and data group, posted a 19 per cent fall in full year net profit to £1.2bn after Covid-19 disrupted its events business. The company retained a target of becoming net-zero emissions business by 2050, saying that its emissions peaked in 2018, while setting new milestones to reduce its net intensity by between 6 per cent and 8 per cent versus 2016 levels by 2023, and by 20 per cent by 2030.
Related companies
Make a complaint about Microsoft by viewing their customer service contacts.
